H. pylori Eradication: Triple Therapy, Bismuth Quadruple & Microbiome Recovery

1. The Biology of H. pylori: How a Bacterium Colonises Acid

Helicobacter pylori is a gram-negative, microaerophilic bacterium shaped like a tight helix — a morphology that is not incidental. The spiral form combined with four to six unipolar flagella allows it to drill through viscous gastric mucus, reaching the protected epithelial surface where pH is closer to neutral and immune surveillance is lower.

Urease: the acid-neutralising engine

The organism produces extraordinary quantities of urease, an enzyme that hydrolyses urea (present in gastric secretions) into ammonia and carbon dioxide. The ammonia cloud locally neutralises acid, creating a microenvironment the bacterium can survive in. This biochemistry is not only a survival mechanism — it is also the biological basis of the urea breath test used in diagnosis.

CagA and VacA: the virulence apparatus

Not all H. pylori strains are equal. The most clinically important virulence factors are encoded on the Cag pathogenicity island (CagPAI). Strains carrying this island inject the CagA protein directly into gastric epithelial cells via a type IV secretion system. Once inside, CagA disrupts cell signalling, promotes proliferation, suppresses apoptosis, and reorganises the cytoskeleton in ways that accelerate malignant transformation.

VacA (vacuolating cytotoxin A) is a pore-forming toxin secreted by most strains at varying activity levels. VacA vacuolates epithelial cells, disrupts mitochondrial membrane potential, and critically, suppresses T-cell immune responses — helping the bacterium evade adaptive immunity even in the presence of a detectable antibody response.

The combination of persistent inflammation (driven by IL-8, TNF-α, and reactive oxygen species), direct oncogenic signalling from CagA, and immune evasion via VacA creates a decades-long carcinogenic process — from normal mucosa through chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, to gastric adenocarcinoma.

IARC Group 1 classification

In 1994, the International Agency for Research on Cancer (IARC) classified H. pylori as a Group 1 definite human carcinogen — the highest classification, meaning sufficient evidence exists in humans. It is the most common infectious cause of cancer globally, responsible for an estimated 810,000 new cancer cases per year. This is not a marginal association: it is one of the most robust causal relationships in oncology.

2. Epidemiology: Who Carries It and Why

H. pylori infects an estimated 4.4 billion people worldwide — roughly 50% of the global population, though prevalence varies dramatically by region, age, and socioeconomic status. In low-income countries with limited sanitation, prevalence exceeds 70-80%. In high-income countries it has fallen to 20-40%, primarily through improved water sanitation, refrigeration, and antibiotic exposure (often incidental from childhood treatment of other infections).

Transmission is primarily oral-oral (saliva, vomit) and fecal-oral (contaminated water or food). Most infections are acquired in childhood, frequently within households. Once established, the bacterium persists indefinitely without treatment — there is no documented spontaneous clearance in adults.

The clinical spectrum of H. pylori infection ranges from asymptomatic carriage (the majority), through chronic non-atrophic gastritis, peptic ulcer disease (duodenal or gastric), atrophic gastritis, gastric adenocarcinoma, and the rarer gastric MALT lymphoma. Roughly 10-15% of infected individuals develop peptic ulcers over a lifetime, and 1-3% develop gastric cancer — a fraction that translates into millions of cases given the enormous infected population.

3. Diagnosis: Choosing the Right Test

Accurate diagnosis is non-negotiable — both before treatment and after. The choice of test depends on clinical context, whether endoscopy is indicated, medication history, and whether this is pre- or post-eradication testing.

Urea Breath Test (UBT)

The urea breath test is widely considered the gold standard non-invasive test for active infection. The patient ingests radiolabelled urea (C-13 or C-14); if H. pylori is present, its urease cleaves the urea, and labelled CO₂ is detected in exhaled breath. Sensitivity and specificity both exceed 95%. Key caveat: proton pump inhibitors (PPIs) suppress urease activity and create false negatives. PPIs must be stopped at least 2 weeks before testing. Antibiotics and bismuth must be stopped at least 4 weeks before.

Stool Antigen Test (SAT)

The monoclonal antibody-based stool antigen test detects H. pylori antigens in feces. Sensitivity and specificity are approximately 94% and 97% respectively. Like the UBT, it is suppressed by PPIs and antibiotics. It is the preferred non-invasive test in children and is equivalent to UBT for post-treatment confirmation. It is significantly cheaper and requires no specialised equipment, making it the predominant test in primary care and resource-limited settings.

Serology: significant limitations

Serum IgG antibody testing is widely available and inexpensive, but carries critical limitations. Serology cannot distinguish active from past (successfully treated) infection because antibody titres remain elevated for months to years after eradication. It should not be used to confirm treatment success. Its role is limited to initial screening in populations with low PPI use, or in clinical contexts where other tests are unavailable. Sensitivity is approximately 85% and specificity 79% — substantially below UBT and SAT.

Endoscopy and biopsy

Upper endoscopy with biopsy allows direct visualisation of the gastric mucosa plus multiple diagnostic options from tissue: rapid urease test (CLO test), histology with Giemsa or Warthin-Starry staining, and culture with antibiotic susceptibility testing. Endoscopy is indicated when alarm features are present (dysphagia, weight loss, bleeding, age over 60 with new dyspepsia, family history of gastric cancer), when empirical treatment has failed, or when susceptibility-guided therapy is being planned. Culture with sensitivity testing is the only way to directly identify antibiotic resistance patterns, which is increasingly relevant as clarithromycin resistance rises globally.

4. Eradication Regimens: From Triple to Quadruple Therapy

The choice of eradication regimen is increasingly driven by regional antibiotic resistance patterns, particularly clarithromycin resistance. Guidelines from the European Helicobacter and Microbiota Study Group (Maastricht VI/Florence), the American College of Gastroenterology, and the Toronto Consensus all now incorporate local resistance data as the primary determinant of first-line therapy.

Standard Triple Therapy

Standard triple therapy (STT) consists of a proton pump inhibitor (PPI) + amoxicillin 1g + clarithromycin 500mg, all twice daily for 14 days. For decades this was the universal first-line regimen. However, global clarithromycin resistance has risen sharply — exceeding 20% in much of Europe, Southeast Asia, and North America. In high-resistance populations, STT achieves eradication rates as low as 70-75%, falling well below the 90% threshold considered acceptable for first-line therapy. In regions with confirmed clarithromycin resistance below 15%, STT may still be appropriate, but this threshold is met in fewer and fewer places.

Bismuth Quadruple Therapy (BQT)

Bismuth quadruple therapy is now recommended as first-line by most major guidelines in regions with high clarithromycin resistance. The regimen consists of:

• PPI (standard dose twice daily)
• Bismuth subcitrate 120mg four times daily (or bismuth subsalicylate)
• Tetracycline 500mg four times daily
• Metronidazole 500mg three to four times daily

Duration is 10 to 14 days. Eradication rates of 85-95% are consistently reported in meta-analyses, including in populations with high metronidazole resistance — bismuth appears to partially overcome this resistance. Bismuth compounds also have direct bactericidal effects on H. pylori independent of the antibiotic components. A pre-packaged formulation (Pylera) combining bismuth subcitrate potassium, tetracycline, and metronidazole simplifies dosing adherence.

Concomitant Therapy

Concomitant therapy is a four-drug regimen without bismuth: PPI + amoxicillin + clarithromycin + metronidazole, all twice daily for 10-14 days. It achieves eradication rates of 85-90% in many studies and has the advantage of once-daily or twice-daily dosing that improves adherence. It is particularly useful in regions with moderate (not very high) clarithromycin resistance.

Levofloxacin-Based Regimens

Levofloxacin triple therapy (PPI + amoxicillin + levofloxacin) is a common second-line or salvage regimen in cases where clarithromycin-based therapy has failed. Eradication rates are 75-90% in second-line use. However, fluoroquinolone resistance is rising rapidly — exceeding 20% in many regions — limiting its utility where susceptibility testing is unavailable. Sequential and hybrid levofloxacin-bismuth regimens are also employed in complicated salvage situations.

Post-Treatment Confirmation: The Non-Negotiable Step

Confirming eradication is mandatory after any treatment course — a step that is frequently omitted in primary care settings. The recommended approach is UBT or stool antigen test, performed at least 4 weeks after completing antibiotics and at least 2 weeks after stopping PPIs. Early testing or testing while still on PPIs yields false negatives and creates a false sense of cure, leaving a significant fraction of patients with active infection.

Serology must never be used for post-treatment confirmation. Treatment failure triggers a second-line regimen, ideally informed by susceptibility testing if available. After two failures, endoscopy with culture is strongly recommended before any third attempt.

5. Microbiome Disruption and Recovery

Antibiotic-based eradication therapy is a controlled insult to the gut microbiome. The same drugs that eliminate H. pylori also suppress, shift, or eliminate large populations of commensal bacteria. Understanding the scope of this disruption — and what accelerates recovery — is central to optimising long-term outcomes after treatment.

The scale of antibiotic disruption

Studies using 16S rRNA sequencing and shotgun metagenomics have documented that H. pylori eradication regimens cause rapid, significant shifts in microbiome composition. Lactobacillus and Bifidobacterium species are particularly sensitive to clarithromycin and metronidazole. Clostridiales diversity, which anchors colonisation resistance, is also reduced. Some studies show that overall alpha diversity (species richness) drops by 20-40% within days of starting therapy.

A key question is how long recovery takes. The literature converges on a difficult answer: substantially longer than the treatment course itself. Most microbiome parameters recover to near-baseline within 1 to 3 months, but complete compositional recovery — including restoration of less abundant keystone species — can take 6 to 12 months. Some studies using high-resolution sequencing have detected persistent compositional shifts beyond 12 months in a subset of patients, particularly in those who received multiple or longer courses of antibiotics.

Probiotics during eradication: the Dore 2019 evidence

A landmark 2019 meta-analysis by Dore et al., published in Medicine, synthesised data from 40 randomised controlled trials examining probiotic supplementation alongside H. pylori eradication therapy. The findings were clinically meaningful:

• Probiotic supplementation significantly increased overall eradication rates (OR 1.68, 95% CI 1.38-2.03)
• Significant reduction in antibiotic-associated side effects including diarrhea, nausea, vomiting, and epigastric pain
• Improved adherence to therapy (fewer discontinuations due to adverse effects)
• Effect size varied by strain — multi-strain preparations and those containing Lactobacillus species showed strongest effects

Lactobacillus rhamnosus GG (LGG) is among the most extensively studied strains in antibiotic-associated contexts. It has demonstrated ability to persist transiently in the GI tract during antibiotic treatment, competitively exclude pathogens, and produce bacteriocins with direct activity against H. pylori. LGG combined with standard eradication therapy has shown eradication rate improvements of 5-12 percentage points in individual trials.

Sulforaphane: the broccoli compound

Sulforaphane, the isothiocyanate derived from glucoraphanin in cruciferous vegetables (especially broccoli sprouts), has demonstrated direct antimicrobial activity against H. pylori in cell culture and in murine models. Human pilot data (Haristoy et al., 2003; Yanaka et al., 2009) suggest it reduces bacterial load and attenuates gastritis-associated biomarkers. It activates Nrf2, reducing oxidative stress in the inflamed gastric epithelium. While not a replacement for antibiotic therapy, sulforaphane is used as an adjunct in integrative gastroenterology protocols for both active infection support and post-eradication mucosal recovery.

Mastic gum

Mastic gum, the resin of Pistacia lentiscus, has been used in Mediterranean cultures for gastrointestinal complaints for millennia. In vitro studies have shown bactericidal activity against H. pylori including some antibiotic-resistant strains. A small human study (Huwez et al., 1998) demonstrated significant reduction in symptoms and bacterial load with 1g/day mastic gum. The mechanism appears to involve disruption of H. pylori's outer membrane and inhibition of urease. Evidence remains preliminary compared with antibiotic-based regimens, and mastic gum should not be used as monotherapy for eradication — but it may have a role as an adjunct for symptom management and mucosal healing.

Zinc Carnosine for mucosal repair

Zinc L-carnosine (a chelate of zinc and the dipeptide L-carnosine) has a well-established role in gastric mucosal cytoprotection in Japan, where it has been approved as a pharmaceutical (Polaprezinc) since 1994. It enhances mucus production, inhibits H. pylori urease activity, reduces oxidative stress in the gastric epithelium, and promotes mucosal healing. Clinical studies have demonstrated its ability to reduce gastric erosions and attenuate H. pylori-associated gastritis as an adjunct to standard therapy. Post-eradication mucosal repair protocols frequently include zinc carnosine for 8-12 weeks to support epithelial recovery.

The GutCode H. pylori Protocol

This is not a substitute for medical care. Eradication requires prescription antibiotics and must be confirmed with a validated post-treatment test. This protocol frames the sequence of steps that the evidence supports.

Related Reading